OMC
OVID icon

Oasis Management Company’s Ovid Therapeutics OVID Stock Holding History

Oasis Management Company’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-270,000
Closed -$502K – 101
2022
Q4 		$502K Hold
270,000
– – 0.1% 67
2022
Q3 		$497K Buy
270,000
+201,200
+292% +$421K 0.08% 84
2022
Q2 		$148K Buy
+68,800
New +$166K 0.03% 116

Other funds holding OVID

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Oasis Management Company's OVID Position: Q1 2023 in Review

Oasis Management Company sold out of Ovid Therapeutics (OVID) in Q1 2023, closing a stake of 270,000 shares — an estimated $502K sold.

Oasis Management Company first reported a position in OVID in Q2 2022 and held it in 3 quarters. The position peaked at $502K in Q4 2022. 60 funds tracked by Wall St. Rank hold OVID as of Q1 2023.

  • Oasis Management Company reported no remaining Ovid Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Oasis Management Company sold 270,000 Ovid Therapeutics shares in Q1 2023, an estimated $502K.
  • Oasis Management Company first reported a position in Ovid Therapeutics in Q2 2022 and held it in 3 quarters.
  • Oasis Management Company's Ovid Therapeutics position peaked at $502K in Q4 2022.
  • 60 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2023.

Based on Oasis Management Company's 13F filing for Q1 2023, filed 15 May 2023.